COMMUNIQUÉS West-GlobeNewswire

Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
15/03/2018
NEWTOWN, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a [...]
BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today [...]
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
15/03/2018
MADISON, Wis., March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]
Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
15/03/2018
SEL-212 Severe Gout Program on Track; Additional Phase 2 Data for Higher Dose Cohorts to be Presented on April 9 th or 10 th , 2018 at PANLAR Congress Phase 1 Clinical Trial of SEL-403 for Mesothelioma Initiated Company [...]
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018
15/03/2018
Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and 2) MT-5111, an Engineered Toxin Body with a novel MOA against HER2 positive cancers AUSTIN, Texas, March 15, 2018 (GLOBE [...]
Extendicare Announces March 2018 Dividend of C$0.04 per Share
15/03/2018
MARKHAM, Ontario, March 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
THRC’s CEO Calvin H. Knowlton, PhD Interviewed on NPR’s It’s Your Health
15/03/2018
MOORESTOWN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (“TRHC”) (NASDAQ: TRHC ), Chairman and CEO Calvin H. Knowlton, PhD, recently conducted an interviewed with NPR’s Lisa Davis, host of It’ [...]
Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, [...]
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
15/03/2018
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC ) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients [...]
HempAmericana Issues New Letter to Shareholders
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) CEO issues the following letter to Shareholders: Dear Valued Shareholder, Today is 30th day that we have [...]
Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]
Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 28 th Annual Oppenheimer [...]
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
15/03/2018
PHILADELPHIA and OXFORD, U.K., March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today reported three partial responses (two confirmed and one [...]
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that preclinical data for TG-1601, the Company’s novel BET inhibitor, has been selected for presentation at the [...]
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
15/03/2018
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “ [...]
Mustang Bio Announces Key Leadership Appointments
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]
FIT Biotech Oy: FIT Biotech's Review of Operations and Financial Statement 2017 published
15/03/2018
FIT Biotech Oy Company announcement, March 15, 2018 at 12:30 EET FIT Biotech's Review of Operations and Financial Statement 2017 published FIT Biotech's Review of Operations and Financial Statement for the year 2017 [...]
Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
15/03/2018
Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation ( [...]
Vical Reports Fourth Quarter 2017 Financial and Operational Results
15/03/2018
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today reported financial results for the three months ended December 31, 2017. Net loss for the fourth quarter of 2017 was $3.7 million, [...]

Pages